Numerous states have pending physician-aided dying (PAD) legislation. Little research has been done regarding use of PAD, or ways to improve the process and/or results.
P hysician aid-in-dying (PAD) refers to a physician providing a terminally ill patient with a prescription for a lethal dose of medication that the patient intends to use to end his or her own life.
1 Oregon put forth the Death with Dignity Act (DWDA) in 1994, and it became law in 1997. Oregon was the first state to enact such legislation. The act has requirements protecting prescribers and users from civil and criminal liability. All PAD candidates must (1) be Oregon residents (duration unspecified), (2) be certified by 2 physicians to have a life expectancy of less than 6 months, (3) have drugs prescribed by an MD or DO licensed in Oregon, (4) be capable of making and communicating health care decisions for themselves, and (5) be able to selfadminister the medication. 2 The patient must make 2 oral requests and 1 written request for PAD, over a minimum period of 15 days. Alternatives, including comfort care, hospice, and pain control are offered. Patients are told at several points that they may rescind the request. The Oregon Health Authority (OHA) is legally obligated to collect compliance and prescribing information, and it produces an annual report that includes basic demographic information, the number of prescriptions written, and the number of patients taking the lethal medication. 3 Requests for additional data may be made. Patient confidentiality is guaranteed, and the OHA will not disclose whether an individual physician participates. We examined DWDA data to determine usage and effectiveness, and to gauge promising cancer care delivery research areas.
Methods
We reviewed OHA website reports from 1998 to 2015. 3 We also made a supplemental data request to the state concerning the numbers of physicians participating and prescriptions written per physician. Summary data, including user demographics, medication efficacy and toxic effects, and underlying reasons for patients requesting and using PAD, were gathered. These data, including patient ethnicity and time to coma and death, were assessed by the prescribing physician. We compared trends in death rates vs prescriptions written using logistic regression. 4 These were also evaluated using
Poisson regression, adjusting for temporal changes in the Oregon population. 5 The Oregon Health and Science University Office of Integrity deemed the study IRB-exempt because the study used publicly available data recorded in such a manner that participants could not be identified.
Results
A total of 1545 prescriptions were written, and 991 (64%) patients ingested the medications and subsequently died. DWDA deaths make up only a small fraction of overall Oregon resident mortality, with a rate of 38.6 per 10 000 total deaths. 3 From 1998 to 2013, the number of prescriptions written had
Key Points
Question How is physician-aided dying being used in Oregon?
Findings In this analysis of publicly available data, about two-thirds of patients prescribed lethal medication under Oregon's Death with Dignity act consumed the medication and subsequently died. Cancer was the most common underlying disease.
Meaning Physician aid-in-dying makes up only a small fraction of Oregon resident deaths, accounting for 38.6 deaths per 10 000 total deaths, but it offers considerable potential benefits to many patients who are near the end of their life. Of 991 patients, 52 (5.3%) were referred to psychiatrists for determination of competence. Forty-six (4.7%) were in longterm care facilities when they self-administered, and 1 individual was a hospital inpatient. Physicians were present at the time of ingestion in 148 cases (16.1%). Between 2001 and 2015, 855 (93.5%) patients notified families of their intention to use DWDA medication, and 928 (94.0%) took the medicine at home.
Pure pentobarbital was a commonly used lethal drug until it became unavailable in 2012. 6 Secobarbital use accounted for 580 (58.5%) deaths. Information on drug effectiveness and complications was requested on all patients from 1998 to 2010; after that only in cases when a health care provider was present at the time of death. The median time to coma was 5 minutes (range, 1-38 minutes). Patients rarely remained unconscious for long periods; median time to death was 25 minutes, but the range was 1 minute to more than 4 days. The medications were relatively devoid of unexpected toxic effects. Vomiting was unusual (24 patients, 2.4%). Six patients awakened, giving the medications an efficacy rate of 99.4%.
Cancer was the most common underlying terminal illness, with 762 (77.1%) patients (Table) . Seventy-nine (8.0%) patients had amyotrophic lateral sclerosis, and 44 (4.5%) and 26 (2.6%), respectively, had incurable lung and heart disease. Nine patients (0.9%) had HIV or AIDS. Lung cancer was the most common malignant abnormality, with 177 (17.9%) cases, and breast cancer was the second most frequent, with 73 (7.4%) patients.
Sex was relatively evenly divided, with 509 men (51.4%) and 482 (48.6%) women dying. Most of those dying (953, 96.6%) were white. Ninety-four patients (approximately 10%) were aged younger than 55 years. The youngest was 25. There were 145 (14.6%) patients who were 85 years or older and the eldest recorded user of DWDA medication was 102 years old. The median age was 71 years.
Most (865, 90.5%) patients were enrolled in hospice and had insurance. Most (708 71.9%) had at least some college education.
Patients had a variety of reasons for requesting DWDA medication, as assessed by the prescribing physician. Nine-hundred three (92%) perceived loss of autonomy. Of 897 patients, 885 patients (89.7%) were unable to participate in enjoyable activities, and 677 (78.7%) cited loss of dignity. Few (474, 48.2%) worried about control of bodily functions. Two hundred forty-eight (25.2%) patients stated inadequate pain control contributed to their decision. A minority (30; 3.1%) of patients were concerned about treatment costs.
Discussion
Other studies have surveyed physician and patient attitudes toward PAD and described patient demographics in the United States and Europe, 7 but this work is more detailed in terms of providing data on prescriptions received, patients consuming the lethal medications, and actual deaths. Oregon itself has the longest US experience with PAD. This study describes usage over the life of the Oregon DWDA and, to our knowledge, it is the most inclusive to date. Review of this period during which PAD has been legal is quite revealing and might guide future efforts to legalize PAD and/or help physicians caring for terminally ill patients. We found that approximately two-thirds of patients having prescriptions written took the lethal medication(s), and nearly all died (>99%) when they did so. Cancer was the most common underlying terminal disease.
Though the rate of prescriptions written annually has increased steadily, this was not a result of simple growth in the Oregon resident population or increases in cancer death rates-both increasing by approximately 1.0% from 2014 to 2015 (Figure) . Presumably the increase was at least in part related to further social acceptance of the DWDA. Notably, PAD deaths still make up well below 0.5% of citizen mortality in Oregon.
Inadequate symptom palliation has been cited as a reason patients seek PAD. Patients' end-of-life concerns appear difficult to palliate, however; the most commonly cited reasons for taking lethal medications were loss of autonomy and dignity, and inability to enjoy life. A minority (248, 25.2%) of cases were associated with inadequate pain control, though that figure should be lower. In addition, although few patients were referred for psychiatric evaluation with questions of competency, increasing access to therapists and counseling for other purposes (eg, meaning-centered group psychotherapy, which has been demonstrated to improve spiritual well-being and end-of-life sense of meaning), could substantially help patients considering PAD. 8 
Limitations
The quality of our data is limited by the fact the attending physicians supplied the state with the underlying information (ie, primary records, such as death certificates, were not checked). In addition, because the physicians attested to the patients' reasons for requesting DWD there is no way to ascertain whether the questioning of the patient was comprehensive.
Conclusions
We believe PAD is a promising area for formal, prospective research. Capturing more information on patients considering it (eg, how many had an underlying diagnosis of depression, whether tumors were primary or recurrent, and time since diagnosis) would be of great interest in guiding cancer care delivery research. It would be helpful to understand why patients prescribed lethal medications do or do not take them, whether an algorithm can be derived to advise patients on how long the medications will require to work, and whether we can better palliate end-of-life concerns, avoiding or delaying PAD. Author Contributions: Dr Blanke had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. 
